Pro-Assurance Corp (PRA) 52.05 $PRA ProAssurance is a

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pro-Assurance Corp (PRA) 52.05 $PRA

ProAssurance is a Ward's 50 Company for the Tenth Straight Year
PR Newswire - Tue Jul 12, 3:30PM CDT
ProAssurance Corporation (NYSE: PRA) has again been named to the prestigious Ward's 50. This marks the tenth straight year that The Ward Group recognized ProAssurance's outstanding performance and named it one of America's 50 finest property-casualty insurance companies.
PRA: 52.05 (+0.07)

AmTrust Financial and its Units Affirmed Ratings by A.M. Best
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:04AM CDT
Credit rating giant, A.M. Best recently affirmed the issuer credit rating (ICR) of "bbb" of AmTrust Financial Services, Inc. (AFSI).
PRA: 52.05 (+0.07), AFSI: 24.87 (+0.13), TPRE: 12.25 (+0.21)

ProAssurance Corporation Announces Dates for Second Quarter Earnings Release and Conference Call
PR Newswire - Fri Jul 08, 7:00AM CDT
ProAssurance Corporation (NYSE: PRA) will report results for the second quarter of 2016 after the close of normal New York Stock Exchange trading on Wednesday, August 3, 2016.
PRA: 52.05 (+0.07)

ProAssurance (PRA) Set to Grow on Buyouts: Will You Hold?
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 8:24AM CDT
On Jun 29, 2016 we issued an updated research report on ProAssurance Corporation (PRA).
PRA: 52.05 (+0.07), NGHC: 21.30 (+0.32), OB: 14.16 (+0.11), MKL: 934.11 (-5.47)

ProAssurance's Growth Prospects Dull Amid High Expenses
Zacks Equity Research - Zacks Investment Research - Fri May 27, 9:08AM CDT
On May 27, 2016, we issued an updated research report on ProAssurance Corporation (PRA).
CINF: 76.09 (-0.07), PRA: 52.05 (+0.07), NMIH: 5.83 (+0.12), MKL: 934.11 (-5.47)

ProAssurance Announces Results from 2016 Annual Meeting of Shareholders
PR Newswire - Wed May 25, 3:31PM CDT
Shareholders of ProAssurance Corporation (NYSE: PRA), acting at today's Annual Meeting of Shareholders, overwhelmingly elected Bruce D. Angiolillo to our Board, and also overwhelmingly re-elected John J. McMahon, Jr. and W. Stancil Starnes to our Board. Each received at least 95% of the votes cast by shareholders and will serve a three-year term ending at the Annual Meeting of Shareholders in 2019 and until their successors are elected and qualified.
PRA: 52.05 (+0.07)

ProAssurance Declares Quarterly Dividend
PR Newswire - Wed May 25, 3:30PM CDT
The Board of Directors of ProAssurance Corporation (NYSE: PRA) has declared a cash dividend of $0.31 per common share, payable on July 8, 2016 to shareholders who own our stock as of June 24, 2016.
PRA: 52.05 (+0.07)

Infinity Property and Casualty Corporation Holds Annual Meeting of Shareholders
PR Newswire - Tue May 17, 4:15PM CDT
Infinity Property and Casualty Corporation (NASDAQ: IPCC) today announced that the shareholders elected the nine director nominees to the Board of Directors at today's Annual Shareholders' Meeting. Other actions taken at the Annual Meeting included the approval by the shareholders of the proposals to ratify the appointment of Ernst & Young LLP as Infinity's independent registered public accounting firm, and to approve, on an advisory basis, the compensation of Infinity's named executive officers.
PRA: 52.05 (+0.07), IPCC: 82.42 (-0.67)

ProAssurance (PRA) Q1 Earnings, Revenues Meet Estimates
Zacks Equity Research - Zacks Investment Research - Tue May 10, 9:00AM CDT
ProAssurance Corporation (PRA) reported first-quarter 2016 operating earnings per share of 46 cents, in line with the Zacks Consensus Estimate.
PGR: 33.26 (-0.25), RLI: 68.60 (+0.22), PRA: 52.05 (+0.07), FAF: 41.68 (+0.35)

ProAssurance Reports Results for First Quarter 2016
PR Newswire - Mon May 09, 5:45AM CDT
ProAssurance Corporation (NYSE: PRA) reports the following results for First Quarter of 2016:
PRA: 52.05 (+0.07)

ProAssurance Announces Preliminary Results for First Quarter 2016
PR Newswire - Thu Apr 28, 3:30PM CDT
ProAssurance Corporation (NYSE: PRA) announced today that, despite strong underlying fundamentals in its insurance operations, we expect to report net income of between $0.35 and $0.37 per diluted share and operating earnings of between $0.45 and $0.47 per diluted share when we release final first quarter results on May 9, 2016. We anticipate net earned premium in the quarter of approximately $177 million and a consolidated combined ratio of approximately 94.5%.
PRA: 52.05 (+0.07)

ProAssurance Corporation Announces Date for First Quarter Earnings Release and Conference Call
PR Newswire - Mon Apr 11, 7:00AM CDT
ProAssurance Corporation (NYSE: PRA) will report results for the first quarter of 2016 prior to the opening of normal New York Stock Exchange trading on Monday, May 9, 2016.
PRA: 52.05 (+0.07)

ProAssurance Corporation Announces Dates for Fourth Quarter Earnings Release and Conference Call
PR Newswire - Mon Jan 25, 3:30PM CST
ProAssurance Corporation (NYSE: PRA) will report results for the fourth quarter of 2015 after the close of normal New York Stock Exchange trading on Tuesday, February 23, 2016.
PRA: 52.05 (+0.07)

Upgrade Alert for ProAssurance (PRA)
Comtex SmarTrend(R) - Thu Jan 21, 8:08AM CST
ProAssurance (NYSERA) was upgraded from Neutral to Buy at SunTrust today. The stock closed yesterday at $46.22 on volume of 252,000 shares, below average daily volume of 272,000. ProAssurance has overhead space with shares priced $46.22, or 11.8% below the average consensus analyst price target of $52.40. The stock should find initial resistance at its 200-day moving average (MA) of $48.46 and further resistance at its 50-day MA of $50.37.
PRA: 52.05 (+0.07)

ProAssurance's Capital Actions Look Good, Costs a Drag
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 10:50AM CST
We issued an updated research report on ProAssurance Corporation (PRA) on Dec 10, 2015.
CINF: 76.09 (-0.07), HALL: 11.37 (+0.12), PRA: 52.05 (+0.07), HRTG: 12.21 (+0.11)

ProAssurance Shares More Profit, OK's Special Dividend
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 3:35PM CST
In order to increase shareholder worth, the board of directors of ProAssurance Corporation (PRA) has declared a special dividend of $1.00 per share.
UIHC: 16.00 (+0.05), RLI: 68.60 (+0.22), PRA: 52.05 (+0.07), IPCC: 82.42 (-0.67)

ProAssurance declares special and regular quarterly dividends
M2 - Thu Dec 03, 5:27AM CST
The board of directors of ProAssurance Corporation (NYSERA) approved a special and regular common stock dividend of USD1.00 and USD0.31 per share, the company disclosed on Wednesday.
PRA: 52.05 (+0.07)

ProAssurance Announces Special Dividend
PR Newswire - Wed Dec 02, 3:18PM CST
The ProAssurance Corporation (NYSE: PRA) Board of Directors has authorized a special dividend of $1.00 per common share and a regular quarterly dividend of $0.31 per common share. Both dividends will be paid on January 8, 2016 to shareholders who own our stock as of December 24, 2015.
PRA: 52.05 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 7

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 2

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 1

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 5

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 2

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 1

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 3

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 8

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 1

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

IMCD Expands Reach in Latin America with Blumos Acquisition

Updated Category News Views 88

IMCD Expands Reach in Latin America with Blumos Acquisition IMCD N.V. is making significant strides in the life science markets across Latin America through its recent acquisition of the Blumos Group. This move showcases IMCD's commitment to growing its footprint in the region, enhancing its distribution of specialty chemicals and ingredients. About Blumos Group Founded...

Continue Reading
Insights on the Recent Decline of SolarEdge Technologies (SEDG)

Updated Category News Views 129

Understanding the Decline of SolarEdge Technologies SolarEdge Technologies Inc (NASDAQ: SEDG) recently faced a notable decline in its stock price, falling by 5.47% to $17.96. This drop is part of a broader downward trend affecting clean energy stocks, triggered by concerns surrounding the pricing strategies and performance expectations of major players in the solar energy...

Continue Reading
FCP Secures $16.7M for Multifamily Project in Lake Nona

Updated Category News Views 191

FCP Closes $16.7 Million for Royal Palm at Nona Development FCP has announced a significant milestone by closing a $16.7 million preferred equity investment aimed at financing the Royal Palm at Nona project. This 320-unit, Class A multifamily development is set to rise in a rapidly growing submarket. The development is spearheaded by Royal Palm Companies, a reputable firm...

Continue Reading
TeamLinkt Receives Growth Investment to Expand AI Sports Platform

Updated Category News Views 318

TeamLinkt Gains Momentum with Strategic Investment TeamLinkt, a groundbreaking sports management platform, proudly announces a significant minority growth investment from Growth Street Partners. This investment marks an exciting chapter for TeamLinkt as it aims to enhance its technology and expand support services for sports leagues, clubs, and associations....

Continue Reading
Glucose Health Validates Fiber's Importance for Public Well-Being

Updated Category News Views 102

Glucose Health, Inc. Shines a Light on Dietary Fiber's Importance In an important recognition, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Agriculture (USDA) have identified dietary fiber as a nutrient of public health concern. This announcement holds significant weight for Glucose Health, Inc. (OTC: GLUC), a leader in diabetic...

Continue Reading